Trends in hypnotic drug use in depression 2007-2017: A Swedish population-based study.
Z‐drugs
benzodiazepines
depression
drug utilisation
hypnotic and sedatives
melatonin
Journal
Journal of sleep research
ISSN: 1365-2869
Titre abrégé: J Sleep Res
Pays: England
ID NLM: 9214441
Informations de publication
Date de publication:
14 Jun 2024
14 Jun 2024
Historique:
revised:
01
03
2024
received:
16
06
2023
accepted:
29
05
2024
medline:
14
6
2024
pubmed:
14
6
2024
entrez:
14
6
2024
Statut:
aheadofprint
Résumé
Insomnia is a common feature of depression; however, depression treatment guidelines provide limited recommendations regarding hypnotic drugs. Few studies have thoroughly investigated the use of hypnotic drugs in depression. In this cohort study using national Swedish registers, we included all patients ≥18 years with incident unipolar depression during 2007-2017. Patients were followed for 3 years, noting the annual and quarterly prevalence of hypnotic drug use from prescription fills. Prevalence ratios (PR) comparing 2017 to 2007 were calculated with 95% confidence intervals (CI). A total of 222,077 patients with depression were included (mean age 41 years, 59% women). In the year following diagnosis, 44.1% used any hypnotic drug in 2017, compared with 46.7% in 2007 (PR 0.94, 95% CI 0.92-0.97). The most commonly used drugs were Z-drugs (zopiclone, zolpidem, and zaleplon) with a prevalence of 27.6% in 2017 and 35.6% in 2007 (PR 0.78, 95% CI 0.75-0.80). Melatonin use increased sharply to 12.0% in 2017 from 0.4% in 2007 (PR 28.9, 95% CI 23.5-35.7). Hypnotic drug use was most prevalent in the first two quarters after diagnosis; however, after 3 years, the quarterly prevalence was still 19.2%. Hypnotics were more common among women, older patients, those with somatic comorbidities, more severe depression, or a history of suicide attempt. Evidence from this large register-based study demonstrates that hypnotics were used to a large extent in depression in Sweden 2007-2017. Z-drugs use declined and melatonin use increased dramatically. Hypnotic drug use remained high even 3 years after diagnosis.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e14267Subventions
Organisme : Janssen Pharmaceuticals
ID : Contract 5-63/2015
Informations de copyright
© 2024 The Author(s). Journal of Sleep Research published by John Wiley & Sons Ltd on behalf of European Sleep Research Society.
Références
Agargun, M. Y., Besiroglu, L., Cilli, A. S., Gulec, M., Aydin, A., Inci, R., & Selvi, Y. (2007). Nightmares, suicide attempts, and melancholic features in patients with unipolar major depression. Journal of Affective Disorders, 98(3), 267–270. https://doi.org/10.1016/j.jad.2006.08.005
American Psychiatric Association. (2010). Practice Guideline for the Treatment of Patients With Major Depressive Disorder (3 ed.). https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf
Baglioni, C., Battagliese, G., Feige, B., Spiegelhalder, K., Nissen, C., Voderholzer, U., Lombardo, C., & Riemann, D. (2011). Insomnia as a predictor of depression: A meta‐analytic evaluation of longitudinal epidemiological studies. Journal of Affective Disorders, 135(1–3), 10–19. https://doi.org/10.1016/j.jad.2011.01.011
Bennabi, D., Yrondi, A., Charpeaud, T., Genty, J. B., Destouches, S., Lancrenon, S., Allaili, N., Bellivier, F., Bougerol, T., Camus, V., Doumy, O., Dorey, J. M., Haesebaert, F., Holtzmann, J., Lançon, C., Lefebvre, M., Moliere, F., Nieto, I., Rabu, C., … Courtet, P. (2019). Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental). BMC Psychiatry, 19(1), 50. https://doi.org/10.1186/s12888-019-2025-7
Bertisch, S. M., Herzig, S. J., Winkelman, J. W., & Buettner, C. (2014). National use of prescription medications for insomnia: NHANES 1999‐2010. Sleep, 37(2), 343–349. https://doi.org/10.5665/sleep.3410
Caillet, P., Rousselet, M., Gerardin, M., Jolliet, P., & Victorri‐Vigneau, C. (2020). Prevalence of zolpidem use in France halved after secure prescription pads implementation in 2017: A SNDS database nested cohort study. PLoS One, 15(2), e0228495. https://doi.org/10.1371/journal.pone.0228495
Charlson, M. E., Pompei, P., Ales, K. L., & MacKenzie, C. R. (1987). A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. Journal of Chronic Diseases, 40(5), 373–383. https://doi.org/10.1016/0021-9681(87)90171-8
Chellappa, S. L., & Araújo, J. F. (2007). Sleep disorders and suicidal ideation in patients with depressive disorder. Psychiatry Research, 153(2), 131–136. https://doi.org/10.1016/j.psychres.2006.05.007
Fang, H., Tu, S., Sheng, J., & Shao, A. (2019). Depression in sleep disturbance: A review on a bidirectional relationship, mechanisms and treatment. Journal of Cellular and Molecular Medicine, 23(4), 2324–2332. https://doi.org/10.1111/jcmm.14170
Furihata, R., Otsuki, R., Hasegawa, N., Tsuboi, T., Numata, S., Yasui‐Furukori, N., Kashiwagi, H., Hori, H., Ochi, S., Muraoka, H., Onitsuka, T., Komatsu, H., Takeshima, M., Hishimoto, A., Nagasawa, T., Takaesu, Y., Nakamura, T., Asami, T., Miura, K., … Hashimoto, R. (2022). Hypnotic medication use among inpatients with schizophrenia and major depressive disorder: Results of a nationwide study. Sleep Medicine, 89, 23–30. https://doi.org/10.1016/j.sleep.2021.11.005
Hämäläinen, J., Isometsä, E., Sihvo, S., Kiviruusu, O., Pirkola, S., & Lönnqvist, J. (2009). Treatment of major depressive disorder in the Finnish general population. Depression and Anxiety, 26(11), 1049–1059. https://doi.org/10.1002/da.20524
Harris, L. M., Huang, X., Linthicum, K. P., Bryen, C. P., & Ribeiro, J. D. (2020). Sleep disturbances as risk factors for suicidal thoughts and behaviours: A meta‐analysis of longitudinal studies. Scientific Reports, 10(1), 13888. https://doi.org/10.1038/s41598-020-70866-6
Hertenstein, E., Feige, B., Gmeiner, T., Kienzler, C., Spiegelhalder, K., Johann, A., Jansson‐Fröjmark, M., Palagini, L., Rücker, G., Riemann, D., & Baglioni, C. (2019). Insomnia as a predictor of mental disorders: A systematic review and meta‐analysis. Sleep Medicine Reviews, 43, 96–105. https://doi.org/10.1016/j.smrv.2018.10.006
Hertenstein, E., Trinca, E., Wunderlin, M., Schneider, C. L., Züst, M. A., Fehér, K. D., Su, T., Straten, A. V., Berger, T., Baglioni, C., Johann, A., Spiegelhalder, K., Riemann, D., Feige, B., & Nissen, C. (2022). Cognitive behavioral therapy for insomnia in patients with mental disorders and comorbid insomnia: A systematic review and meta‐analysis. Sleep Medicine Reviews, 62, 101597. https://doi.org/10.1016/j.smrv.2022.101597
Højlund, M., Gudmundsson, L. S., Andersen, J. H., Saastamoinen, L. K., Zoega, H., Skurtveit, S. O., Wastesson, J. W., Hallas, J., & Pottegård, A. (2023). Use of benzodiazepines and benzodiazepine‐related drugs in the Nordic countries between 2000 and 2020. Basic & Clinical Pharmacology & Toxicology, 132(1), 60–70. https://doi.org/10.1111/bcpt.13811
Johansson, M., Jansson‐Fröjmark, M., Norell‐Clarke, A., & Linton, S. J. (2021). Changes in insomnia as a risk factor for the incidence and persistence of anxiety and depression: A longitudinal community study. Sleep Science and Practice, 5(1), 5. https://doi.org/10.1186/s41606-020-00053-z
Karlsson, B., Johnell, K., Sigström, R., Sjöberg, L., & Fratiglioni, L. (2016). Depression and depression treatment in a population‐based study of individuals over 60 years old without dementia. The American Journal of Geriatric Psychiatry, 24(8), 615–623. https://doi.org/10.1016/j.jagp.2016.03.009
Kennedy, S. H., Lam, R. W., McIntyre, R. S., Tourjman, S. V., Bhat, V., Blier, P., Hasnain, M., Jollant, F., Levitt, A. J., MacQueen, G. M., McInerney, S. J., McIntosh, D., Milev, R. V., Müller, D. J., Parikh, S. V., Pearson, N. L., Ravindran, A. V., & Uher, R. (2016). Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the Management of Adults with major depressive disorder:Section 3. Pharmacological treatments. The Canadian Journal of Psychiatry, 61(9), 540–560. https://doi.org/10.1177/0706743716659417
Khan, A. A., Gardner, C. O., Prescott, C. A., & Kendler, K. S. (2002). Gender differences in the symptoms of major depression in opposite‐sex dizygotic twin pairs. The American Journal of Psychiatry, 159(8), 1427–1429. https://doi.org/10.1176/appi.ajp.159.8.1427
Kishi, T., Matsunaga, S., & Iwata, N. (2017). Efficacy and tolerability of Z‐drug adjunction to antidepressant treatment for major depressive disorder: A systematic review and meta‐analysis of randomized controlled trials. European Archives of Psychiatry and Clinical Neuroscience, 267(2), 149–161. https://doi.org/10.1007/s00406-016-0706-5
Li, C., Ma, D., Li, M., Wei, T., Zhao, X., Heng, Y., Ma, D., Anto, E. O., Zhang, Y., Niu, M., & Zhang, W. (2022). The therapeutic effect of exogenous melatonin on depressive symptoms: A systematic review and meta‐analysis [systematic review]. Frontiers in Psychiatry, 13, 737972. https://doi.org/10.3389/fpsyt.2022.737972
Li, J., Somers, V. K., Xu, H., Lopez‐Jimenez, F., & Covassin, N. (2022). Trends in use of melatonin supplements among US adults, 1999‐2018. Jama, 327(5), 483–485. https://doi.org/10.1001/jama.2021.23652
Li, L., Wu, C., Gan, Y., Qu, X., & Lu, Z. (2016). Insomnia and the risk of depression: A meta‐analysis of prospective cohort studies. BMC Psychiatry, 16(1), 375. https://doi.org/10.1186/s12888-016-1075-3
Ludvigsson, J. F., Andersson, E., Ekbom, A., Feychting, M., Kim, J. L., Reuterwall, C., Heurgren, M., & Olausson, P. O. (2011). External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 450. https://doi.org/10.1186/1471-2458-11-450
Malhi, G. S., Bell, E., Bassett, D., Boyce, P., Bryant, R., Hazell, P., Hopwood, M., Lyndon, B., Mulder, R., Porter, R., Singh, A. B., & Murray, G. (2021). The 2020 Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for mood disorders. The Australian and New Zealand Journal of Psychiatry, 55(1), 7–117. https://doi.org/10.1177/0004867420979353
McCall, W. V., Benca, R. M., Rosenquist, P. B., Riley, M. A., McCloud, L., Newman, J. C., Case, D., Rumble, M., & Krystal, A. D. (2017). Hypnotic medications and suicide: Risk, mechanisms, mitigation, and the FDA. The American Journal of Psychiatry, 174(1), 18–25. https://doi.org/10.1176/appi.ajp.2016.16030336
McClintock, S. M., Husain, M. M., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Trivedi, M. H., Cook, I., Morris, D., Warden, D., & Rush, A. J. (2011). Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. Journal of Clinical Psychopharmacology, 31(2), 180–186. https://doi.org/10.1097/JCP.0b013e31820ebd2c
Medalie, L., & Cifu, A. S. (2017). Management of Chronic Insomnia Disorder in adults. Jama, 317(7), 762–763. https://doi.org/10.1001/jama.2016.19004
Morton, I., & Hall, J. (2012). Concise dictionary of pharmacological agents: Properties and synonyms. Springer Science & Business Media.
National Institute for Health and Care Excellence. (2022). Depression in adults: treatment and management (update). (9781904671855). NICE Retrieved from https://www.nice.org.uk/guidance/ng222
Oh, C.‐M., Kim, H. Y., Na, H. K., Cho, K. H., & Chu, M. K. (2019). The effect of anxiety and depression on sleep quality of individuals with high risk for insomnia: A population‐based study [original research]. Frontiers in Neurology, 10, 849. https://doi.org/10.3389/fneur.2019.00849
Ohayon, M. M. (2002). Epidemiology of insomnia: What we know and what we still need to learn. Sleep Medicine Reviews, 6(2), 97–111. https://doi.org/10.1053/smrv.2002.0186
Qaseem, A., Barry, M. J., & Kansagara, D. (2016). Nonpharmacologic versus pharmacologic treatment of adult patients with major depressive disorder: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 164(5), 350–359. https://doi.org/10.7326/m15-2570
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of Chronic Insomnia Disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133. https://doi.org/10.7326/m15-2175
Riemann, D., Baglioni, C., Bassetti, C., Bjorvatn, B., Dolenc Groselj, L., Ellis, J. G., Espie, C. A., Garcia‐Borreguero, D., Gjerstad, M., Gonçalves, M., Hertenstein, E., Jansson‐Fröjmark, M., Jennum, P. J., Leger, D., Nissen, C., Parrino, L., Paunio, T., Pevernagie, D., Verbraecken, J., … Spiegelhalder, K. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675–700. https://doi.org/10.1111/jsr.12594
Riemann, D., Espie, C. A., Altena, E., Arnardottir, E. S., Baglioni, C., Bassetti, C. L. A., Bastien, C., Berzina, N., Bjorvatn, B., Dikeos, D., Dolenc Groselj, L., Ellis, J. G., Garcia‐Borreguero, D., Geoffroy, P. A., Gjerstad, M., Gonçalves, M., Hertenstein, E., Hoedlmoser, K., Hion, T., … Spiegelhalder, K. (2023). The European insomnia guideline: An update on the diagnosis and treatment of insomnia 2023. Journal of Sleep Research, 32(6), e14035. https://doi.org/10.1111/jsr.14035
Riemann, D., Krone, L. B., Wulff, K., & Nissen, C. (2020). Sleep, insomnia, and depression. Neuropsychopharmacology, 45(1), 74–89. https://doi.org/10.1038/s41386-019-0411-y
Rzepka‐Migut, B., & Paprocka, J. (2020). Efficacy and safety of melatonin treatment in children with autism Spectrum disorder and attention‐deficit/hyperactivity disorder‐a review of the literature. Brain Sciences, 10(4), 219. https://doi.org/10.3390/brainsci10040219
Sakurai, H., Suzuki, T., Yoshimura, K., Mimura, M., & Uchida, H. (2017). Predicting relapse with individual residual symptoms in major depressive disorder: A reanalysis of the STAR*D data. Psychopharmacology, 234(16), 2453–2461. https://doi.org/10.1007/s00213-017-4634-5
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American Academy of sleep medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. https://doi.org/10.5664/jcsm.6470
Sivertsen, B., Salo, P., Mykletun, A., Hysing, M., Pallesen, S., Krokstad, S., Nordhus, I. H., & Øverland, S. (2012). The bidirectional association between depression and insomnia: The HUNT study. Psychosomatic Medicine, 74(7), 758–765. https://doi.org/10.1097/PSY.0b013e3182648619
Sunderajan, P., Gaynes, B. N., Wisniewski, S. R., Miyahara, S., Fava, M., Akingbala, F., Deveaugh‐Geiss, J., Rush, A. J., & Trivedi, M. H. (2010). Insomnia in patients with depression: A STAR*D report. CNS Spectrums, 15(6), 394–404. https://doi.org/10.1017/s1092852900029266
The National Board of Health and Welfare. (2022). National Prescribed Drug Register. https://www.socialstyrelsen.se/en/statistics-and-data/registers/national-prescribed-drug-register/
The National Board of Health and Welfare. (2023). Statistic database for prescriptions. https://sdb.socialstyrelsen.se/if_lak/val.aspx
Tubbs, A. S., Fernandez, F. X., Ghani, S. B., Karp, J. F., Patel, S. I., Parthasarathy, S., & Grandner, M. A. (2021). Prescription medications for insomnia are associated with suicidal thoughts and behaviors in two nationally representative samples. Journal of Clinical Sleep Medicine, 17(5), 1025–1030. https://doi.org/10.5664/jcsm.9096
Urrila, A. S., Karlsson, L., Kiviruusu, O., Pelkonen, M., Strandholm, T., & Marttunen, M. (2012). Sleep complaints among adolescent outpatients with major depressive disorder. Sleep Medicine, 13(7), 816–823. https://doi.org/10.1016/j.sleep.2012.04.012
Wettermark, B., Hammar, N., Fored, C. M., Leimanis, A., Otterblad Olausson, P., Bergman, U., Persson, I., Sundström, A., Westerholm, B., & Rosen, M. (2007). The new Swedish Prescribed Drug Register‐opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiology and Drug Safety, 16(7), 726–735. https://doi.org/10.1002/pds.1294
Winkelman, J. W. (2015). Insomnia disorder. New England Journal of Medicine, 373(15), 1437–1444. https://doi.org/10.1056/NEJMcp1412740
Wong, J., Murray Horwitz, M., Bertisch, S. M., Herzig, S. J., Buysse, D. J., & Toh, S. (2020). Trends in dispensing of zolpidem and low‐dose trazodone among commercially insured adults in the United States, 2011‐2018. Jama, 324(21), 2211–2213. https://doi.org/10.1001/jama.2020.19224